Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Apathy in Parkinson's disease: A systematic review and meta‐analysis

View through CrossRef
AbstractApathy is a frequently reported neuropsychiatric symptom in Parkinson's disease (PD), but its prevalence and clinical correlates are debated. We aimed to address these issues by conducting a systematic review and meta‐analysis. Embase, Medline/PubMed, and PsychINFO databases were searched for relevant studies. Data were extracted by two independent observers, using predefined extraction forms tailored specifically to the research question. From 1,702 titles and abstracts, 23 studies were selected. Meta‐analysis showed a prevalence of apathy in PD of 39.8% (n = 5,388, 905% CI 34.6‐45.0%). Apathy was associated with higher age (3.3 years, 95% CI = 1.7‐4.9), lower mean Mini‐Mental State Evaluation (MMSE) score (−1.4 points, 95% CI = −2.1 to −0.8), an increased risk of co‐morbid depression (relative risk [RR] = 2.3, 95% CI = 1.9‐2.8), higher Unified Parkinson's Disease Rating Scale (UPDRS) motor score (6.5 points, 95% CI = 2.6‐10.3), and more severe disability (Hedges‐G = 0.5, 95% CI = 0.3‐0.6). Half of the patients with apathy had concomitant depression (57.2%, 95% CI = 49.4‐64.9%), and this estimate was similar after exclusion of patients with cognitive impairment (52.5%, 95% CI = 42.2%‐62.8%). In conclusion, we found that apathy affects almost 40% of patients with PD. Several factors influence reported prevalence rates, contributing to the considerable heterogeneity in study results. Half of patients with apathy do not suffer from concomitant depression or cognitive impairment, confirming its status as a separate clinical syndrome in PD. The pervasiveness of apathy in PD warrants research into its treatment, although different underlying pathophysiological mechanisms may require different treatment strategies. Treatment of apathy could improve patient quality of life, reduce caregiver burden, alleviate disability by increasing motivation for self‐care, and reduce cognitive impairment by improving executive functioning. © 2015 International Parkinson and Movement Disorder Society
Title: Apathy in Parkinson's disease: A systematic review and meta‐analysis
Description:
AbstractApathy is a frequently reported neuropsychiatric symptom in Parkinson's disease (PD), but its prevalence and clinical correlates are debated.
We aimed to address these issues by conducting a systematic review and meta‐analysis.
Embase, Medline/PubMed, and PsychINFO databases were searched for relevant studies.
Data were extracted by two independent observers, using predefined extraction forms tailored specifically to the research question.
From 1,702 titles and abstracts, 23 studies were selected.
Meta‐analysis showed a prevalence of apathy in PD of 39.
8% (n = 5,388, 905% CI 34.
6‐45.
0%).
Apathy was associated with higher age (3.
3 years, 95% CI = 1.
7‐4.
9), lower mean Mini‐Mental State Evaluation (MMSE) score (−1.
4 points, 95% CI = −2.
1 to −0.
8), an increased risk of co‐morbid depression (relative risk [RR] = 2.
3, 95% CI = 1.
9‐2.
8), higher Unified Parkinson's Disease Rating Scale (UPDRS) motor score (6.
5 points, 95% CI = 2.
6‐10.
3), and more severe disability (Hedges‐G = 0.
5, 95% CI = 0.
3‐0.
6).
Half of the patients with apathy had concomitant depression (57.
2%, 95% CI = 49.
4‐64.
9%), and this estimate was similar after exclusion of patients with cognitive impairment (52.
5%, 95% CI = 42.
2%‐62.
8%).
In conclusion, we found that apathy affects almost 40% of patients with PD.
Several factors influence reported prevalence rates, contributing to the considerable heterogeneity in study results.
Half of patients with apathy do not suffer from concomitant depression or cognitive impairment, confirming its status as a separate clinical syndrome in PD.
The pervasiveness of apathy in PD warrants research into its treatment, although different underlying pathophysiological mechanisms may require different treatment strategies.
Treatment of apathy could improve patient quality of life, reduce caregiver burden, alleviate disability by increasing motivation for self‐care, and reduce cognitive impairment by improving executive functioning.
© 2015 International Parkinson and Movement Disorder Society.

Related Results

Selective serotonin reuptake inhibitors-associated apathy syndrome
Selective serotonin reuptake inhibitors-associated apathy syndrome
Abstract Selective serotonin reuptake inhibitors (SSRIs), commonly used to treat depression, are associated with loss of motivation, anergy, and lack of curiosity often...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
1333 – Study On The Incidence Of Depression And Apathy In a Group Of Patients Diagnosed With Parkinson’s Disease
1333 – Study On The Incidence Of Depression And Apathy In a Group Of Patients Diagnosed With Parkinson’s Disease
IntroductionDepression and apathy are among the most common psychiatric and behavioral disorders associated with Parkinson’s disease (PD). This two psychiatric disorders are major ...
MBI‐apathy, ApoEɛ2, and risk for Alzheimer disease dementia
MBI‐apathy, ApoEɛ2, and risk for Alzheimer disease dementia
AbstractBackgroundApathy, characterized by decreased interest, initiative, and emotional reactivity, is amongst the most common neuropsychiatric symptoms in dementia. However, apat...
Ambulatory actigraphy correlates with apathy in mild Alzheimer’s disease
Ambulatory actigraphy correlates with apathy in mild Alzheimer’s disease
Aim: Apathy is one of the most common behavioral symptoms in Alzheimer’s disease (AD). The aim of our study was to assess the relationship between apathy and locomotor activity in ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Pharmacological treatment of apathy in Parkinson’s disease, review of the literature
Pharmacological treatment of apathy in Parkinson’s disease, review of the literature
Abstract Background Apathy is a highly challenging factor in the general treatment of patients with Parkinson’s disease (PD) and can present a major burden for caregivers. ...
Apathy in Parkinson’s Disease: Defining the Park Apathy Subtype
Apathy in Parkinson’s Disease: Defining the Park Apathy Subtype
Apathy is a neurobehavioural symptom affecting Parkinson’s disease patients of all disease stages. Apathy seems to be associated with a specific underlying non-motor disease subtyp...

Back to Top